For a long period, the golden treatment standard of Dupuytren's disease was surgical treatment. Recently we also have a mini-invasive treatment option, that achieves comparable results with less risk of complications and with significantly shorter recovery time.
It is a treatment by collagenase Clostridium histolyticum. The authors focus on the practical aspects of collagenase therapy.
At the same time, based on their practical experience, the autors provide recommendations on appropriate indications, optimal treatment mode, expected outcomes and treatment limits by collagenase.